A5070237973- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Nuclear Receptors and Signaling
- Autism Spectrum Disorder Research
- RNA regulation and disease
- Autoimmune Neurological Disorders and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Cerebrovascular and genetic disorders
- Neurological and metabolic disorders
- Ginkgo biloba and Cashew Applications
- Cerebral Palsy and Movement Disorders
- Cancer Genomics and Diagnostics
- Genetic Neurodegenerative Diseases
- Neurological diseases and metabolism
- Alzheimer's disease research and treatments
- Pancreatic and Hepatic Oncology Research
- Intracerebral and Subarachnoid Hemorrhage Research
- Tryptophan and brain disorders
- Health Systems, Economic Evaluations, Quality of Life
- Neural and Behavioral Psychology Studies
- Neuroendocrine Tumor Research Advances
- Gout, Hyperuricemia, Uric Acid
- Lysosomal Storage Disorders Research
- Intensive Care Unit Cognitive Disorders
- Peripheral Neuropathies and Disorders
Harvard University
2016-2025
Massachusetts General Hospital
2016-2025
Mercy University Hospital
2012-2025
Cork University Hospital
2014-2025
MaineGeneral Medical Center
2024-2025
Foundation Center
2024
Hadassah Medical Center
2024
Parkinson's Foundation
2022
Institute for Neurodegenerative Disorders
2022
Brigham and Women's Hospital
2016-2022
Objective LRRK2 mutations, the most common genetic cause of Parkinson disease (PD), display incomplete penetrance, indicating importance other and environmental influences on pathogenesis in mutation carriers. The present study investigates whether urate, an antioxidant, Nrf2 activator, inverse risk factor for idiopathic PD, is one such candidate biomarker PD modulation pathogenic Methods Banked plasma samples or urate levels were obtained 3 cohorts age‐ sex‐matched subjects with without a...
<h3>Objective</h3> To identify markers of resistance to developing Parkinson disease (PD) among <i>LRRK2</i> mutation carriers (<i>LRRK2</i>+), we carried out metabolomic profiling in individuals with PD and unaffected controls (UC), without the mutation. <h3>Methods</h3> Plasma from 368 patients UC LRRK2 Cohort Consortium (LCC), comprising 118 <i>LRRK2</i>+/PD+, 115 <i>LRRK2</i>+/UC, 70 <i>LRRK2</i>−/PD+, 65 <i>LRRK2−</i>/UC, CSF available 68 them, were analyzed by liquid chromatography...
Parkinson disease (PD) is a chronic progressive neurodegenerative with increasing worldwide prevalence. Despite many trials of neuroprotective therapies in manifest PD, no disease-modifying therapy has been established. Over the past several decades, series breakthroughs have identified discrete populations at substantially increased risk developing PD. Based on this knowledge, now time to design and implement PD prevention trials. This endeavor builds experience gained from early Alzheimer...
The movement toward prevention trials in people at-risk for Parkinson&rsquo;s is rapidly becoming a reality. authors of this article include genetically advocate with the LRRK2 G2019S variant and two patients rapid eye sleep behavior disorder (RBD), one whom has now been diagnosed disease (PD). These participated as speakers, panelists, moderators &ldquo;Planning Prevention Parkinson&rsquo;s: A Trial Design Forum&rdquo; hosted by Massachusetts General Hospital 2021 2022....
Differentiating multiple system atrophy (MSA) from related neurodegenerative movement disorders (NMD) is challenging. MRI widely available and automated decision-tree analysis simple, transparent, resistant to overfitting. Using a retrospective cohort of heterogeneous clinical MRIs broadly sourced tertiary hospital system, we aimed develop readily translatable fully volumetric diagnostic decision-trees facilitate early accurate differential diagnosis NMDs. 3DT1 171 NMD patients (72 MSA, 49...
Abstract Background The G2019S mutation of LRRK2, which enhances kinase activity the protein, confers a substantial risk developing Parkinson’s disease (PD). However, demonstrates incomplete penetrance, suggesting involvement other genetic or environmental modulating factors. Here, we investigated whether LRRK2 knock-in (KI) mice treated with inflammogen lipopolysaccharide (LPS) could model PD. Results We found that short-term (2 weeks) treatment LPS did not result in loss dopaminergic...
The aim of this study was to assess the neuropsychological behavior Parkinson's disease (PD) patients with addictive behaviors. Characteristically, these have younger onset PD, higher novelty-seeking personality traits, jump conclusions, and often make irrational choices. We assessed whether PD without behaviors deficits in a sequential sampling task, called secretary problem. In participants needed pick best out multiple offers. Critically, once rejected deal, option became unavailable....
Objective: The objective of this study was to investigate the long-term outcome in subjects who had epileptiform abnormalities on EEG. Background: Abnormal electroencephalogram (EEG) is a predictor seizures. Previous studies investigating risk seizures were mostly focused neonates, post-epilepsy surgery or those with encephalopathic patterns periodic lateralised epileptiform discharges EEG. M ethods: We performed retrospective review EEGs 2004 tertiary care centre. included and follow-up...